Chinook Therapeutics to Present at the Oppenheimer 33rd Annual Healthcare Conference
Chinook Therapeutics (Nasdaq: KDNY) announced its participation in a virtual fireside chat at the Oppenheimer 33rd Annual Healthcare Conference on March 14, 2023, at 3:20 pm ET. The management will also engage in one-on-one meetings during the event. Investors can access the live webcast and an archived recording on the Investors section of Chinook’s website, available for 90 days post-event.
Chinook Therapeutics focuses on developing precision medicines for kidney diseases, with notable programs like atrasentan for IgA nephropathy in phase 3, and BION-1301 in phase 1/2 trials.
- None.
- None.
SEATTLE, March 07, 2023 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (Nasdaq: KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for kidney diseases, today announced that Chinook management is scheduled to participate in a virtual fireside chat at the Oppenheimer 33rd Annual Healthcare Conference on Tuesday, March 14, 2023 at 3:20 pm ET, as well as 1x1 meetings.
To access the live webcast and subsequent archived recording of this and other company presentations, please visit the Investors section of Chinook’s website. The archived webcast will remain available for replay on Chinook’s website for 90 days.
About Chinook Therapeutics, Inc.
Chinook Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing precision medicines for kidney diseases. Chinook’s product candidates are being investigated in rare, severe chronic kidney disorders with opportunities for well-defined clinical pathways. Chinook’s lead program is atrasentan, a phase 3 endothelin receptor antagonist for the treatment of IgA nephropathy and proteinuric glomerular diseases. BION-1301, an anti-APRIL monoclonal antibody, is being evaluated in a phase 1/2 trial for IgA nephropathy. CHK-336, an oral small molecule LDHA inhibitor for the treatment of hyperoxalurias, is being evaluated in a phase 1 clinical trial in healthy volunteers. In addition, Chinook’s research and discovery efforts are focused on building a pipeline of precision medicines for rare, severe chronic kidney diseases with defined genetic and molecular drivers. Chinook is leveraging insights from kidney single cell RNA sequencing and large CKD patient cohorts that have been comprehensively panomically phenotyped, with retained biosamples and prospective clinical follow-up, to discover and develop therapeutic candidates with mechanisms of action targeted against key kidney disease pathways. To learn more, visit www.chinooktx.com.
FAQ
What is Chinook Therapeutics' participation in the Oppenheimer 33rd Annual Healthcare Conference?
How can I access the webcast of Chinook Therapeutics' presentation?
What are the key programs being developed by Chinook Therapeutics?
How long will the archived webcast of the conference be available?
What is the focus of Chinook Therapeutics' research?
